<DOC>
	<DOCNO>NCT00140816</DOCNO>
	<brief_summary>Foods contain dairy fat ( thus high proportion short medium chain fatty acid possibly nutrient micronutrient effect energy intake , satiety energy metabolism ) affect energy balance metabolic profile subject prone develop abdominal adiposity metabolic syndrome . The aim study test hypothesis intake dairy product favorable effect marker metabolic syndrome . To explore hypothesis participant free live situation extend study period .</brief_summary>
	<brief_title>Dairy Products Metabolic Effects ( Norwegian Part )</brief_title>
	<detailed_description />
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<criteria>Apparently healthy men woman age 3065 year : BMI &lt; 35 kg/m2 . Having sign write informed consent Limited habitual intake dairy product accord dietary questionnaire . Traits metabolic syndrome two follow criterion fulfil : Fasting plasma glucose ≥ 6.1 mmol/l Serum triglycerides ≥ 1.7 mmol/l Serum HDL cholesterol &lt; 1.0 mmol/l ( 40 mg/dl ) ( men ) &lt; 1.3 mmol/l ( 50 mg/dl ) ( woman ) Blood pressure ≥130/ 85 mmHg Waist circumference &gt; 94cm ( men ) &gt; 88cm ( woman ) . Patients follow condition include trial : Known Type 1 diabetes , treat type 2 diabetes . With HbA1c ≥ 7,5 % first blood sample . Pregnant lactating woman . Known abnormal thyroid hormone level , high thyroid stimulate hormone ( TSH ) level . Having receive investigational drug last 30 day date randomisation . Unable unwilling comply protocol . Likely withdraw study completion . Concomitant medication : With lipid lower drug ( fibrate , statin ) within last 6 week randomisation . Treated antidiabetic drug . Treated Cyclosporin A . Change within last 6 week randomisation study medication could interfere lipid profile ( i.e. , anti hypertensive drug , oral corticosteroid , thyroid hormone , retinoids , thiazidic derivative , hormone replacement therapy ) . Treated oral anticoagulant . Treated protease inhibitor ( indinavir , ritonavir , saquinavir ) Treated obesity : medical treatment within last 6 week ( orlistat , sibutramine ) and/or surgery ( gastroplasty , bypass ) . Associated disease condition : Diabetic ketoacidosis , diabetic precoma . Current chronic pancreatitis , identify risk know history acute pancreatitis . Hepatic insufficiency , acute alcohol intoxication , alcoholism . Known cholelithiasis without cholecystectomy . AST and/or ALT &gt; 2 time upper normal limit ( UNL ) . Renal failure renal dysfunction define serum creatinine level &gt; 135 µmol/L male &gt; 110 µmol/L female . Recent myocardial infarction ( within 3 month prior randomisation ) , Known gastric peptic ulcer intestinal disease within previous 3 month randomisation capable modify intestinal absorption drug . Any severe pathology cancer , mental illness , etc , opinion investigator might pose risk patient confound result study . Blood pressure &gt; 160/100 mmHg . Body weight change exceed ± 5 % total body weight last three month admission . Drugs affect lipid glucose metabolism , weight reduce drug , antihypertensive drug know metabolic effect .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2009</verification_date>
</DOC>